Skip to content

Seegene and BD Form Worldwide Collaboration to Develop Multiplex Molecular Diagnostic Assays

Published on GenomeWeb MarketWatch RTT News

Seegene and BD Form Worldwide Collaboration to Develop Multiplex Molecular Diagnostic Assays

Seoul, Korea, and Baltimore, MD, September 14, 2015 —  Seegene Inc. (096530.KQ) and BD Life Sciences, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX) today announced that they have entered into a worldwide collaboration agreement to co-develop multiplex real-time PCR reagents for the BD MAX™ System. Under the terms of the agreement, Seegene will develop and manufacture multiplex tests based on novel DPO™, TOCE™, and MuDT™ technologies designed exclusively for BD’s molecular diagnostics platform. BD, in turn, will have worldwide commercialization rights to these tests.
 “We are very pleased to partner with Seegene and incorporate their innovative proprietary technologies into our easy-to-use, fully automated BD MAX™ platform,” said Doug White, VP/GM Molecular Diagnostics and Women’s Health, BD Life Sciences. “With Seegene’s multiplex reagents that simultaneously detect and identify various types of pathogens in a single test, we will continue to expand the BD MAX™ assay portfolio.”
 The BD MAX™ System offers an efficient path to improved clinical outcomes by combining and automating real-time PCR extraction, amplification and detection into a single platform capable of running a wide range of assays across multiple disease states, enabling physicians to address a wide breadth of testing needs. Seegene’s CEO, Dr. Jong-Yoon Chun, added, “Our agreement with BD represents another meaningful milestone to Seegene’s global expansion initiatives in the molecular diagnostics market. BD’s commercial strength in the IVD market will help to bring Seegene’s powerful multiplex PCR chemistry technologies to more physicians and patients worldwide.”

About Seegene
Seegene is the world’s leading developer of multiplex molecular technologies and multiplex clinical molecular diagnostics (M-MoDx). Seegene’s core enabling technologies ACP™, DPO™, READ™, TOCE™, and MuDT™  – are the foundation for M-MoDx tests that can simultaneously detect multiple targets with high sensitivity, specificity and reproducibility.  Seegene’s products detect multi-pathogens with great reliability and throughput, ultimately providing the most economical basis for saving time, labor and cost. Seegene’s mission is to maintain leadership in molecular diagnostics for infectious diseases, genetics, pharmacogenetics, and oncology using innovative proprietary technologies.
About BD
BD is a leading medical technology company that partners with customers and stakeholders to address many of the world’s most pressing and evolving health needs. Our innovative solutions are focused on improving medication management and patient safety; supporting infection prevention practices; equipping surgical and interventional procedures; improving drug delivery; aiding anesthesiology and respiratory care; advancing cellular research and applications; enhancing the diagnosis of infectious diseases and cancers; and supporting the management of diabetes. We are more than 45,000 associates in 50 countries who strive to fulfill our purpose of “Helping all people live healthy lives” by advancing the quality, accessibility, safety and affordability of healthcare around the world. In 2015, BD welcomed CareFusion and its products into the BD family of solutions. For more information on BD, please visit
For more information please visit or call +82 2240 5550 or or call 201.847.6800.

Back To Top